Loss of cell growth control is not sufficient to explain why tumours form as the immune system recognizes many malignant cells and keeps them in check. The local inflammatory microenvironment is a pivotal factor in tumour formation, as tumour-associated inflammation actively suppresses antitumour immunity. The purpose of this review is to evaluate emerging evidence that amino acid catabolism is a key feature of tumour-associated inflammation that supports tumour progression and immune resistance to therapy.
INTRODUCTION
Malignant cells with defective growth control create tumours, but the immune system impedes tumour formation by eliminating many malignant cells ( Fig. 1 ). Some malignant cells progress to form tumours by evading immune checkpoints to establish local microenvironments that protect malignant cells from immune-mediated destruction [1] . Preestablished immune privilege explains tumour resistance to vaccines, which elicit weak clinical responses even if robust immune responses manifest. Tumour cells may suppress antitumour immunity themselves, but tumour-associated inflammation, which extends to draining lymph nodes, is a critical factor regulating antitumour immunity.
The focus of this review is the emerging paradigm that increased amino acid catabolism is a frequent and important feature of inflammation that promotes tumour progression and inhibits antitumour immunity (Fig. 2) . Recent reviews describe immune regulatory pathways involving dendritic cells, macrophages (MFs), myeloid-derived suppressor cells (MDSCs), natural killer (NK), mast cells and Foxp3lineage regulatory CD4 T cells (Tregs) in chronic inflammatory syndromes (Table 1) , including roles in tumour progression and immunotherapy [2,3 && , [4] [5] [6] . Biologic significance is still emerging, but increased amino acid catabolism is commonly associated with inflammation that regulates -rather than stimulates -immunity.
The paradigm that inflammation stimulates immunity is a fundamental tenet of immunology, but inflammation may also drive immune regulation. Thus, interferons are known as 'pro-inflammatory' cytokines, but they also induce immune regulation; moreover, which functional response to interferons is dominant is not always obvious [7] . Local inflammation incited by malignancies that transition into tumours regulates tumour-specific immunity; hence, a therapeutic goal is to convert immune regulatory inflammation into stimulatory inflammation ( Fig. 2) .
Increased amino acid catabolism inhibits immunity in many chronic inflammatory syndromes [7] [8] [9] . Immune tolerance to transplanted skin in mice correlated with enhanced amino acid catabolism in graft-associated dendritic cells [10] , and mast cells expressing tryptophan hydroxylase-1 (TPH-1) promoted tumour relapse after therapy and allograft tolerance [3 && ]. Genetically enhanced Trp catabolism mediated by indoleamine 2,3 dioxygenase (IDO) also suppressed rat lung allograft rejection [11, 12] . Microbial infections often induce IDO (via interferons), which may impede host immunity to promote pathogen persistence, a situation analogous to tumour persistence [8] . Likewise, tumour tolerance is often linked to increased amino acid catabolism, though other regulatory pathways (Table 1 ) may be active simultaneously [13, 14] . Thus, tumours exploit natural immune regulatory pathways that evolved to protect healthy tissues from hyperimmunity. The paradigm that tumours are analogous to aseptic wounds that do not heal is useful, as dying cells release cell contents (including DNA) that are potentially immunostimulatory, but natural regulation may reinforce 'self' tolerance under aseptic conditions.
KEY POINTS
Amino acid catabolism regulates immunity in settings of chronic inflammation, including cancer.
Amino acid catabolism is enhanced prior to clinical presentation and may facilitate tumour progression.
Both amino acid depletion and production of catabolites regulate immunity.
Interventions targeting amino acid catabolism may be effective in adjunct cancer therapies.
Altered amino acid metabolism may yield useful prognostic markers as well as therapeutic targets. 
Initiation
Stages in tumour formation and therapy. Once initiated, malignant lesions promote local inflammation that inhibits immune surveillance to facilitate tumour progression. Eventually, local lymph node involvement suppresses antitumour immunity. Tumour tolerance established prior to clinical presentation is a barrier to successful therapy and creates niches for metastasis and relapse.
AMINO ACID CATABOLISM AND TUMOUR DEVELOPMENT
Genetic predisposition, carcinogens, radiation (UVB, ionizing) or oncogenic viruses synergize to generate malignant dividing cells ( Fig. 1 ). Malignant cells depend on access to essential nutrients such as iron, and iron chelation impedes tumour growth [15] . Correlations between tumour growth and increased local amino acid catabolism (i.e. elevated nutrient consumption) are not consistent with this paradigm. It is important to emphasize that amino acid catabolism triggers profound changes in immune cell functions via amino acid sensors and catabolite receptors, and it may not be necessary to actually 'starve' cells for immune regulatory effects to manifest. Merely reducing the pool of available amino acids may suffice to induce regulatory responses; if so, inhibiting amino acid catabolism may offer therapeutic opportunities. Trp catabolism is the most studied aspect of amino acid catabolism in tumour microenvironments and the recent literature reflects this bias, which was initiated by the finding that IDO activity protected foetal tissues from maternal immunity during pregnancy in mice [16, 17] . However, this discovery was perhaps anticipated by studies over 40 years ago describing increased Trp catabolism in breast and cervical cancer patients [18, 19] . Increased IDO activity often manifests in inflammatory lesions induced by tumour promoters such as oncogenic human papilloma virus (HPV) and murine leukaemia virus (MuLV), phorbolmyristate acetate (PMA or TPA) and UVB radiation [20] [21] [22] [23] [24] , suggesting that Trp catabolism may suppress immune surveillance mechanisms. Indeed, IDO1deficient (IDO1-knockout) mice were more resistant to papilloma formation in the 7,12-dimethylbenz-[a]anthracene/12-O-Tetradecanoylphorbol-13-acetate (DMBA/TPA) model of inflammation-driven carcinogenesis [24] . IDO1-KO mice also exhibited more resistance to lung and breast tumours [25 && ], and IDO1 loss correlated with reduced neo-vascularization, metastasis and impaired functional maturation of MDSCs in the lung tumour model, suggesting that IDO facilitates these tumour supportive functions. However, it is unclear how developing tumours induce IDO. An emerging possibility is that dying tumour cells may trigger local interferon type I (IFNab) production via DNA sensors such as Toll-like receptor-9 (TLR9) or the stimulator of interferon genes (STING) adaptor, which then induces IDO [26, 27] , though excessive STING activation also promotes autoimmunity [28, 29] . Trp catabolites may also promote tumorigenesis, as Trp catabolites activated b-catenin signalling to promote colon tumorigenesis via a T cell independent pathway in mice [30 & ]. Targeting amino acid catabolism may help prevent malignancies developing into tumours, though increased risk of autoimmunity is a potential undesirable consequence of such interventions.
AMINO ACID CATABOLISM IN TUMOUR MICROENVIRONMENTS
Elevated Trp and arginine (Arg) catabolism has been linked to regulation of antitumour immunity. Two different enzymes with oxygen-binding irontetrapyrrole cofactors -IDO and tryptophan 2,3 dioxygenase (TDO) -catalyze oxidative Trp catabolism to generate kynurenine, and TPH-1 converts Trp into serotonin. IDO transcription is induced by IFNab and IFNg in a range of cell types, including selected immune cells, but measuring IDO enzyme activity is important, as posttranslational modifications may be required for IDO activity. Mice and humans possess two linked genes encoding IDO enzymes (IDO1, IDO2). IDO1 mediates regulatory responses to many inflammatory stimuli, including tumour growth [8] . A role for IDO2 has not been defined, though recent studies on IDO2-deficient mice showed that IDO2 and IDO1 control cytokine expression differently and IDO2 did not phenocopy IDO1 in promoting inflammatory skin cancer (G. Prendergast, personal communication). IDO expression occurs in some cancer cells, stromal cells and certain immune cells such as some dendritic cells and MFs in tumour lesions and tumour-draining lymph nodes (TDLNs) in mice and cancer patients. Recent reports continue this trend with studies describing elevated IDO expression in endometrial carcinomas, brain (glioma), chronic lymphocytic leukaemias, nonsmall cell lung cancers and laryngeal squamous cell carcinomas [31] [32] [33] [34] [35] [36] . These studies support the paradigm that IDO regulates antitumour immunity and that IDO is a potential prognostic marker for cancer, reinforcing the rationale for using IDO inhibitors to improve cancer therapy [37] . Phase II oncology trials using IDO inhibitors are ongoing and it remains to be seen whether this novel approach is effective in the clinic, though IDO was identified recently as an immune resistance factor following immunotherapy to block regulatory pathways involving CTLA4, PD-1/L and glucocorticoid-induced tumour necrosis factor (TNF) receptor-related (GITR protein signalling) [38 && ]. Unlike IDO, TDO is expressed primarily in liver and is induced in the central nervous system (CNS) in response to stress-induced glucocorticoids. In liver, TDO regulates serum Trp levels by catabolizing Trp from dietary intake, and TDO expression in liver may account for the observed resistance of liver allografts to rejection [39] . However, some tumour cells express TDO and potential roles for TDO in tumours were reviewed recently revealing striking parallels with the effects of IDO [40, 41] . Thus, TDO-transduced tumour cells were resistant to antitumour immunity and TDO-specific inhibitors restored the ability of mice to reject TDO-expressing tumours [42 & ]. Thus, tumours may evade innate immune tumour surveillance and regulate tumour-specific adaptive immunity by inducing IDO or TDO.
A critical role for TPH-1 in regulating antitumour immunity emerged from studies with TPH-1 deficient mice, which were more resistant to bladder carcinoma cell growth than TPH-1 sufficient mice [3 && ]. Immune resistance was not serotonin dependent, implicating Trp depletion due to TPH-1 enzyme activity in mast cells in metabolic control of antitumour immunity. TPH-1 activity was also shown to be important in regulating skin allograft rejection and suppressing experimental autoimmune encephalitis (EAE). Thus, TPH-1 mediates immune regulation in several inflammatory settings of clinical significance.
Arg is catabolized by two iso-enzymes arginase (ARG) I and II. ARG-I is often coexpressed with nitric oxide synthase (NOS), which competes for Arg as a substrate. Retinoic acid induced ARG-I expression in dendritic cells that promoted Treg differentiation [43] , though MDSCs were reported to inhibit Treg differentiation [44] . Several studies suggest that elevated Arg consumption regulates antitumour immunity. Increased ARG-I expression was detected in MDSCs from cancer patients with squamous cell carcinoma [45] and ARG-II expression was elevated in cancer-associated fibroblasts and correlated with worse outcomes in pancreatic cancer [46 & ]. MDSCs facilitate tumour immune resistance, though these enigmatic cells may use multiple immune regulatory mechanisms, including Trp [47 & ] and Arg catabolism [48] . Moreover, MDSCs developed from fibrocyte precursors in some cancer patients and glutamine (Gln) catabolism promoted MDSC maturation [49, 50] .
MECHANISMS OF IMMUNE REGULATION DRIVEN BY AMINO ACID METABOLISM
How does increased amino acid catabolism inhibit tumorigenesis and therapy? Although not fully resolved, studies in mice with chronic inflammatory syndromes such as tumours have provided some key insights. Amino acid catabolism depletes local pools and generates new catabolites, and amino acid sensors and catabolite receptors sense these changes in immune cells (Fig. 3) .
Amino acid levels are sensed via the mammalian target of rapamycin (mTOR) and general control nonrepressed-2 (GCN2). mTOR is a pivotal checkpoint governing cell cycle entry. Tumour cells may mutate this pathway to facilitate tumour growth and mTOR inhibitors such as everolimus may be effective therapies to control some cancers [51, 52] . Amino acid depletion also restrains antitumour immunity, as mTOR signals promote T cell responses. Hence, local amino acid depletion and treatment with mTOR inhibitors may inhibit antitumour immunity despite the potential to inhibit tumour growth. Trp depletion via IDO to prevent mTOR activation and promote tumour autophagy has been reported [53 & ], but effects on T cell mediated antitumour immunity were not evaluated.
GCN2 is a ribosome-associated kinase that senses binding of uncharged tRNAs. Activated GCN2 kinase incites the integrated stress response to shut down cellular protein synthesis and induce autophagy. GCN2 activation in T cells cultured with IDO-expressing dendritic cells from TDLNs blocked T cell responses to antigens presented by dendritic cells [54] . GCN2 was also required for TDLN dendritic cells to induce Tregs to acquire regulatory phenotypes via IDO [55] . Thus, GCN2 suppresses immunity and promotes immune regulation, though GCN2 activation in tumour cells may block proliferation and induce autophagy. Recent studies attest to the diverse effects of GCN2-mediated cell stress responses on tumour growth and antitumour immunity. Thus, GCN2 promoted tumour angiogenesis [56 & ], inhibited the antitumour effects of IFNab [57] , modified mitochondrial functions in colon cancer cells [58] and supported tumour cell proliferation during restricted access to serine [59] . GCN2 may also impact cancer therapy, as GCN2 induced asparagine synthetase activity (a therapy resistance factor) in paediatric acute lymphoblastic leukaemia (ALL) patients and GCN2 attenuated the efficacy of glucose competitors as antitumour drugs [60, 61] , though GCN2 also promoted the antileukaemic effects of pegylated ARG-I in ALL [62] . Some antitumour reagents mimic the effects of amino acid depletion by inhibiting tRNA charging enzymes to activate GCN2. Thus, the antibiotic borrelidin, which inhibits human threonine tRNAsynthetase, induced apoptosis of ALL cells and GCN2 activation was elevated [63] . Similarly, the antiprotozoal compound halofuginone, which inhibits prolyl-tRNAsynthetase, may also inhibit cancers [64] . However, similar to mTOR, potential diametric effects on tumour cell growth and survival versus immune cell activation and differentiation need to be evaluated carefully, as halofuginone inhibits effector TH17 T cell responses in autoimmune syndromes [65] .
Trp catabolites also mediate potent effects on tumour and immune cells ( Fig. 3) . Kynurenine (Kyn), a Trp catabolite made by cells expressing IDO or TDO, is a natural ligand for the aryl hydrocarbon receptor (AhR), an orphan receptor expressed by many cells [66] . Chemical toxins, known as dioxins, are artificial AhR ligands that have been studied extensively by toxicologists, but relatively little is known about natural AhR ligands such as Kyn. Studies in mice have identified requirements for AhR signalling in T cells, Tregs and dendritic cells to regulate immunity [7, 9] . These findings provide a rationale for mechanistic links between IDO and TDO activity and regulation of antitumour immunity, justifying the use of AhR antagonists as potential therapies to block suppression of antitumour immunity. AhR signalling also enhanced NK cell antitumour activity in mice [67 && ], indicating that AhR signalling can enhance or inhibit immunity, contingent on the physiologic setting [68] . It is unclear how modulation of AhR signals will impact outcomes in cancer, as AhR signals may mediate direct effects on tumour, stromal or immune cells to impede or promote tumour progression, survival, angiogenesis and antitumour immunity. Hence, the effects of ligands that modulate AhR signalling (in either direction) in settings of tumour growth and treatment require more rigorous evaluation in physiologic settings of tumour growth to discern the impact of such interventions. For example, studies that Trp catabolites made by cells expressing IDO and TDO confer resistance to gliomas should be weighed against the known neurotoxic effects of some Trp catabolites [69, 70] .
In summary, the downstream consequences of increased amino acid catabolism in tumour microenvironments are profound but complex, diametric and poorly defined. More studies to evaluate the role of specific pathways in physiologic settings of tumour development and therapy will be necessary to further elucidate specific contributions to tumour growth, survival and antitumour immunity.
CONCLUSION
Immune tolerance created by tumours is a major barrier to effective chemotherapy, radiotherapy and immunotherapy, and subsequent tumour relapse is associated with renewal of local tolerance. Increased amino acid catabolism may occur from the earliest stages of tumorigenesis due to inflammation associated with the formation of malignant lesions that protects malignant cells from immune surveillance. Oncogenic viral infections, chemicals and radiation that promote carcinogenesis also stimulate increased amino acid catabolism that contributes to the local inflammatory responses to these insults and promotes resistance to natural and therapy-induced antitumour immunity.
